RxDoctor Payments Data

Gary Bronstein, MD

Cardiovascular Disease · Roseburg, ORNPI 1932284528

Payments from drug & device makers

$3,085in general payments, 2019–2025

Across 209 payments — averaging $14.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$767
  • AstraZeneca$374
  • Pfizer$363
  • Cook Medical LLC$149
  • Abbott$145
  • Amgen$125
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,085100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,085 in reported general payments places this provider in the 65th percentile of 198 cardiovascular disease providers in Oregon.

See all cardiovascular disease providers in Oregon

Medicare billing

Part B allowed, 2024
$149,367
Medicare patients
1,180
Services billed
2,661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban747$698,522
XareltoRivaroxaban269$272,988
JardianceEmpagliflozin375$269,467
EntrestoSacubitril/Valsartan141$146,482
FarxigaDapagliflozin Propanediol200$141,872
Repatha SureclickEvolocumab88$57,985
MultaqDronedarone Hcl17$20,336
Metoprolol Succinate934$14,679
Praluent PenAlirocumab24$11,471
Atorvastatin Calcium726$9,813
VascepaIcosapent Ethyl16$8,378
Ranolazine ErRanolazine65$8,001
Amiodarone Hcl177$7,997
Isosorbide Mononitrate ErIsosorbide Mononitrate382$7,827
Nebivolol Hcl122$5,264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$363$698,522747 claims
Johnson & JohnsonXarelto$109$272,988269 claims
Boehringer IngelheimJardiance$56$269,467375 claims
NovartisEntresto$767$146,482141 claims
AstraZenecaFarxiga$374$141,872200 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 198 cardiovascular disease providers in Oregon.

Other cardiovascular disease in Roseburg

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →